Ifosfamide

Indication
Ewing sarcoma of bone and articular cartilage of unspecified sites

INN
Ifosfamide

Medicine type
Chemical agent

List type
Complementary

Formulations
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection

EML status history
First added in 2009 (TRS 958)
Changed in 2015 (TRS 994)

Sex
All

Age
Also recommended for children

Therapeutic alternatives
The recommendation is for this specific medicine

Patent information
Patents have expired in most jurisdictions
Read more about patents.

Tags
Cancer

Wikipedia
Ifosfamide

DrugBank
Ifosfamide

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for Ewing sarcoma was specifically endorsed. Additionally, ifosfamide was added on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Ewing sarcoma is attached.

Expert Committee report